|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
PL2624865T3
(pl)
|
2010-10-06 |
2018-11-30 |
Regeneron Pharmaceuticals, Inc. |
Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
|
|
BR112013018740A2
(pt)
|
2011-01-28 |
2019-01-08 |
Sanofi Sa |
anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
CN103930444B
(zh)
|
2011-09-16 |
2020-08-04 |
瑞泽恩制药公司 |
用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
|
|
EP2790681B9
(en)
|
2011-11-18 |
2023-07-26 |
Regeneron Pharmaceuticals, Inc. |
Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying
|
|
AU2013212587B2
(en)
|
2012-01-23 |
2017-07-20 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-Ang2 antibodies
|
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR092325A1
(es)
*
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
WO2014031610A1
(en)
|
2012-08-21 |
2014-02-27 |
Sanofi |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
US9592297B2
(en)
*
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
US8883979B2
(en)
*
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
HRP20181227T1
(hr)
|
2012-09-07 |
2018-10-05 |
Regeneron Pharmaceuticals, Inc. |
Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
|
|
CN106421782A
(zh)
*
|
2012-10-25 |
2017-02-22 |
米迪缪尼有限公司 |
稳定的低粘度抗体配制品
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
TW202021614A
(zh)
|
2013-06-07 |
2020-06-16 |
法商賽諾菲生物技術公司 |
藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
CA2922113C
(en)
|
2013-08-23 |
2023-05-23 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
|
|
US10428157B2
(en)
|
2013-11-12 |
2019-10-01 |
Sanofi Biotechnology |
Dosing regimens for use with PCSK9 inhibitors
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
RU2704999C2
(ru)
|
2014-02-28 |
2019-11-01 |
Ридженерон Фармасьютикалз, Инк. |
Способ лечения кожной инфекции путем введения антагониста il-4r
|
|
PT3613432T
(pt)
*
|
2014-05-07 |
2025-10-29 |
Regeneron Pharma |
Métodos para tratar a polipose nasal através da administração de um antagonista de il-4r
|
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
BR112017003419A2
(pt)
*
|
2014-09-03 |
2017-11-28 |
Medimmune Ltd |
formulação de anticorpo anti-il-4r-alfa estável
|
|
US10066017B2
(en)
*
|
2014-11-14 |
2018-09-04 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
|
|
TWI899515B
(zh)
|
2015-08-04 |
2025-10-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
|
|
MA44238B1
(fr)
|
2016-02-19 |
2024-07-31 |
Regeneron Pharmaceuticals, Inc. |
Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
|
|
EA037960B1
(ru)
|
2016-04-27 |
2021-06-15 |
Эббви Инк. |
Способ лечения эозинофильного эзофагита с применением антитела против il-13
|
|
CN107474134B
(zh)
|
2016-06-08 |
2021-07-27 |
苏州康乃德生物医药有限公司 |
用于结合白细胞介素4受体的抗体
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
CN109789196B
(zh)
|
2016-09-01 |
2024-03-19 |
瑞泽恩制药公司 |
用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
|
|
CN118203659A
(zh)
|
2016-09-22 |
2024-06-18 |
瑞泽恩制药公司 |
用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
|
|
AU2017366870B2
(en)
|
2016-11-29 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
A pharmaceutical composition for averting opioid addiction
|
|
TWI857389B
(zh)
|
2016-12-01 |
2024-10-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
|
EP3558347B1
(en)
|
2016-12-22 |
2026-01-21 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
|
WO2018144773A1
(en)
|
2017-02-01 |
2018-08-09 |
Yale University |
Treatment of diuretic resistance
|
|
JP6172880B1
(ja)
*
|
2017-02-01 |
2017-08-02 |
協和発酵キリン株式会社 |
ダルベポエチンを含む液体医薬組成物
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
JOP20190260A1
(ar)
*
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CN114075269A
(zh)
|
2017-07-06 |
2022-02-22 |
菲仕兰坎皮纳荷兰私人有限公司 |
用于制备糖蛋白的细胞培养工艺
|
|
WO2019028367A1
(en)
|
2017-08-04 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
|
|
PT3515465T
(pt)
|
2017-08-18 |
2024-03-04 |
Regeneron Pharma |
Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
|
|
PL3703818T3
(pl)
|
2017-10-30 |
2024-03-25 |
Sanofi Biotechnology |
Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
|
|
CN111479618B
(zh)
|
2017-12-22 |
2022-08-02 |
瑞泽恩制药公司 |
用于表征药物产品杂质的系统和方法
|
|
JP7395479B2
(ja)
|
2018-01-05 |
2023-12-11 |
ノヴォ ノルディスク アー／エス |
免疫抑制なしにｉｌ－６媒介性炎症を処置する方法
|
|
KR20200115485A
(ko)
|
2018-01-31 |
2020-10-07 |
리제너론 파마슈티칼스 인코포레이티드 |
약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
US12460270B2
(en)
|
2018-02-28 |
2025-11-04 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
BR112020015291B1
(pt)
|
2018-03-19 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc |
Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
EP3793597A1
(en)
|
2018-05-13 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r inhibitor
|
|
EP3833687A1
(en)
|
2018-08-10 |
2021-06-16 |
Regeneron Pharmaceuticals, Inc. |
A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
|
|
CN112218877B
(zh)
|
2018-08-27 |
2025-07-25 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
KR20210053816A
(ko)
|
2018-08-30 |
2021-05-12 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질 복합체를 특성화하기 위한 방법
|
|
JP7467438B2
(ja)
*
|
2018-10-18 |
2024-04-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｒｓｖ抗体の製剤及びその使用方法
|
|
CN113015748B
(zh)
|
2018-10-31 |
2025-12-12 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
EP3878868B1
(en)
|
2018-11-09 |
2024-10-09 |
Ajou University Industry-Academic Cooperation Foundation |
Human antibody having high affinity to human il-4 receptor alpha, and use thereof
|
|
US11312778B2
(en)
|
2018-11-21 |
2022-04-26 |
Brian C. Machler |
Method for treating allergic contact dermatitis
|
|
IL284471B2
(en)
|
2019-01-16 |
2025-01-01 |
Regeneron Pharma |
Methods for identifying free thiols in proteins
|
|
SG11202108627SA
(en)
|
2019-02-18 |
2021-09-29 |
Lilly Co Eli |
Therapeutic antibody formulation
|
|
SG11202109003QA
(en)
|
2019-03-06 |
2021-09-29 |
Regeneron Pharma |
Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
|
|
CN111686247B
(zh)
*
|
2019-03-13 |
2022-07-29 |
苏州康乃德生物医药有限公司 |
包含人白介素-4受体α的抗体的液体组合物
|
|
TW202519263A
(zh)
*
|
2019-03-21 |
2025-05-16 |
美商再生元醫藥公司 |
含有抗il-33抗體之穩定調配物
|
|
MA55372A
(fr)
|
2019-03-21 |
2022-01-26 |
Regeneron Pharma |
Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
|
|
BR112021021195A2
(pt)
|
2019-05-01 |
2022-03-03 |
Regeneron Pharma |
Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33
|
|
EP3969908A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
JP7592064B2
(ja)
|
2019-07-16 |
2024-11-29 |
サノフィ・バイオテクノロジー |
Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
|
|
CN114173819A
(zh)
|
2019-08-05 |
2022-03-11 |
瑞泽恩制药公司 |
通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
|
|
AU2020326713A1
(en)
|
2019-08-05 |
2022-02-17 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
EP4653865A3
(en)
|
2019-09-24 |
2026-02-18 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
MX2022006236A
(es)
|
2019-11-25 |
2022-06-22 |
Regeneron Pharma |
Formulaciones de liberacion sostenida con emulsiones no acuosas.
|
|
EP4073810A1
(en)
|
2019-12-09 |
2022-10-19 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
JP2023508360A
(ja)
|
2019-12-23 |
2023-03-02 |
サノフィ・バイオテクノロジー |
Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
|
|
KR102544013B1
(ko)
|
2020-01-21 |
2023-06-19 |
리제너론 파마슈티칼스 인코포레이티드 |
당질화된 단백질의 전기영동을 위한 탈당질화 방법
|
|
AU2021223128A1
(en)
*
|
2020-02-21 |
2022-09-08 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition containing anti-IL-4R antibody and use thereof
|
|
WO2021195530A1
(en)
|
2020-03-27 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
KR20230015965A
(ko)
|
2020-05-22 |
2023-01-31 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
|
|
CN113797331A
(zh)
*
|
2020-06-16 |
2021-12-17 |
三生国健药业（上海）股份有限公司 |
一种稳定的抗IL-4Rα单克隆抗体液体制剂
|
|
IL299152A
(en)
*
|
2020-07-08 |
2023-02-01 |
Regeneron Pharma |
Stabilized formulations that include antibodies against CTLA-4
|
|
CA3192999A1
(en)
|
2020-08-31 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
US20220169739A1
(en)
|
2020-10-05 |
2022-06-02 |
Sanofi Biotechnology |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
|
EP4251128A1
(en)
|
2020-11-25 |
2023-10-04 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
WO2022133135A1
(en)
|
2020-12-17 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
WO2022150605A1
(en)
|
2021-01-08 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|
|
CN116761880A
(zh)
|
2021-01-20 |
2023-09-15 |
瑞泽恩制药公司 |
改进细胞培养物中的蛋白质滴度的方法
|
|
CA3207883A1
(en)
|
2021-03-03 |
2022-09-09 |
Xiaobin Xu |
Systems and methods for quantifying and modifying protein viscosity
|
|
CA3208011A1
(en)
|
2021-03-17 |
2022-09-22 |
Sarah Harris |
Methods of treating atopic dermatitis with anti il-13 antibodies
|
|
US20220309215A1
(en)
|
2021-03-26 |
2022-09-29 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
|
TW202304507A
(zh)
*
|
2021-04-02 |
2023-02-01 |
美商再生元醫藥公司 |
含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物
|
|
AU2022286340A1
(en)
|
2021-06-01 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
JP2024529434A
(ja)
|
2021-07-26 |
2024-08-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒアンタゴニストを投与することによる慢性自発性蕁麻疹を治療するための方法
|
|
JP2024532263A
(ja)
|
2021-08-23 |
2024-09-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法
|
|
IL310427A
(en)
*
|
2021-08-26 |
2024-03-01 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Pharmaceutical composition of anti-il4r antibody and use thereof
|
|
WO2023039457A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
|
|
AU2022348521A1
(en)
*
|
2021-09-20 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of controlling antibody heterogeneity
|
|
KR20240090312A
(ko)
|
2021-10-07 |
2024-06-21 |
리제너론 파아마슈티컬스, 인크. |
Ph 미터 보정 및 교정
|
|
CN118076894A
(zh)
|
2021-10-07 |
2024-05-24 |
里珍纳龙药品有限公司 |
pH建模和控制的系统及方法
|
|
AU2022369296A1
(en)
|
2021-10-20 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating prurigo nodularis by administering an il-4r antagonist
|
|
KR20240097864A
(ko)
|
2021-10-26 |
2024-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
|
|
EP4433500A1
(en)
|
2021-11-19 |
2024-09-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
|
AU2022425608A1
(en)
|
2021-12-30 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for attenuating atopic march by administering an il-4/il-13 antagonist
|
|
CA3245647A1
(en)
|
2022-03-18 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
METHODS AND SYSTEMS FOR ANALYZING POLYPEPTIDE VARIANTS
|
|
US20240002491A1
(en)
|
2022-04-27 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
|
CA3250514A1
(en)
*
|
2022-05-02 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
ANTI-INTERLEUKIN-4 (IL-4R) RECEPTOR ANTIBODIES
|
|
MA71395A
(fr)
|
2022-07-08 |
2025-04-30 |
Regeneron Pharmaceuticals, Inc. |
Méthodes de traitement de l'oesophagite à éosinophiles chez un sujet pédiatrique par administration d'un antagoniste d'il-4 r
|
|
WO2024047021A1
(en)
|
2022-08-29 |
2024-03-07 |
Sanofi |
Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
|
|
WO2024097714A1
(en)
|
2022-11-01 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hand and foot dermatitis by administering an il-4r antagonist
|
|
WO2024112935A1
(en)
|
2022-11-23 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for improving bone growth by administering an il-4r antagonist
|
|
TW202435942A
(zh)
|
2022-12-16 |
2024-09-16 |
美商里珍納龍藥品有限公司 |
評估層析管柱完整性的方法及系統
|
|
TW202445126A
(zh)
|
2023-01-25 |
2024-11-16 |
美商再生元醫藥公司 |
基於質譜法之體內共表現抗體之表徵
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
TW202445138A
(zh)
|
2023-02-01 |
2024-11-16 |
美商再生元醫藥公司 |
用於生物巨分子分析之具質譜法的不對稱流場流分離
|
|
WO2024178213A2
(en)
|
2023-02-22 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
TW202502819A
(zh)
|
2023-03-22 |
2025-01-16 |
法商賽諾菲生物技術公司 |
藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法
|
|
TW202502820A
(zh)
|
2023-03-27 |
2025-01-16 |
美商再生元醫藥公司 |
藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法
|
|
EP4687971A1
(en)
|
2023-03-30 |
2026-02-11 |
Sandoz Ag |
Stable composition comprising a high protein concentration
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
CN119215163A
(zh)
*
|
2023-06-30 |
2024-12-31 |
百奥泰生物制药股份有限公司 |
抗IL-4Rα抗体制剂及其制备方法和应用
|
|
WO2025017034A1
(en)
|
2023-07-17 |
2025-01-23 |
Formycon Ag |
Stable liquid antibody formulation for dupilumab
|
|
US20250086164A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
US20250108173A1
(en)
|
2023-10-02 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Drug delivery device safety system
|
|
US20250129117A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
US20250145662A1
(en)
*
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025116640A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 당류-프리 액상 제형
|
|
WO2025116637A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 액상 제형
|
|
WO2025116648A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 완충제-프리 액상 제형
|
|
US20250230251A1
(en)
|
2023-12-20 |
2025-07-17 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rb) and related methods
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
EP4623903A1
(en)
|
2024-03-28 |
2025-10-01 |
Fresenius Kabi Deutschland GmbH |
Pharmaceutical composition comprising dupilumab
|
|
US20250388685A1
(en)
|
2024-04-15 |
2025-12-25 |
Sanofi Biotechnology |
Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
|
|
CN118105485B
(zh)
*
|
2024-04-26 |
2024-09-03 |
湖南麦济生物技术有限公司 |
一种稳定的抗人IL-4Rα单克隆抗体制剂
|
|
WO2025247342A1
(zh)
*
|
2024-05-30 |
2025-12-04 |
重庆智翔金泰生物制药股份有限公司 |
包含抗il-4r抗体的药物组合物
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
WO2025264860A2
(en)
|
2024-06-18 |
2025-12-26 |
Yale University |
Methods of treating post-covid airway disease
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
US20260070995A1
(en)
|
2024-09-09 |
2026-03-12 |
Marcella Ruddy |
Methods for treating bullous pemphigoid by administering an il-4r antagonist
|